Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Tirzepatide reduces weight in women with obesity across reproductive stages
Treatment with tirzepatide, compared with placebo, results in significant reductions in body weight, waist circumference, and waist-to-height ratio (WHtR) among women with obesity or overweight and without type 2 diabetes (T2D), regardless of reproductive stage.
Tirzepatide reduces weight in women with obesity across reproductive stages
09 May 2025
MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC
In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).
MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC
09 May 2025
BRCA-negative ovarian cancer gets PFS gains with pembrolizumab plus olaparib
First-line treatment with chemotherapy plus pembrolizumab followed by maintenance with pembrolizumab plus olaparib, with or without bevacizumab, appears to prolong progression-free survival (PFS) in advanced epithelial ovarian cancer without BRCA 1/2 mutations, according to data from the phase III ENGOT-ov43/GOG-3036/KEYLYNK-001 trial.